DTaP and Tdap Vaccines Market Opportunities 2031
MARKET INTRODUCTION
Tdap (Tetanus, Diphtheria, Pertussis) and DTaP (Diphtheria, Tetanus, Pertussis) vaccines contain inactivated forms of the toxin generated by the bacteria that cause the three diseases. The term "inactivated forms" refers to a substance that no longer causes disease but does cause the body to develop antibodies that its immune to the toxins. DTaP is approved for children under the age of seven. Tdap, diphtheria, and pertussis vaccine with a reduced dose is approved for adolescents starting at age 11 and adults ages 19 to 64. It's known as a booster dose because it boosts immunity that has waned from vaccinations given between the ages of 4 and 6.
MARKET DYNAMIC
Factors driving the growth of the DTaP and Tdap vaccines market are the growing number of cases during late spring and early summer, coupled with rising adoption of pertussis vaccine. However, the high cost of vaccine development and inadequate access to vaccines in under-developed countries is expected to hamper the growth of the market. Moreover, increasing high birth rates and rising governments initiatives is anticipated to boost the market growth.
MARKET SCOPE
The "DTaP and Tdap Vaccines Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of DTaP and Tdap vaccines market with detailed market segmentation by product type, age group, and end user. The DTaP and Tdap vaccines market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in DTaP and Tdap vaccines market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The DTaP and Tdap vaccines market is segmented on the basis of product type, age group, and end user. Based on product type, the market is segmented as DTaP vaccine (Diphtheria-Tetanus-acellular Pertussis vaccine), TD (Tetanus and Diphtheria) vaccine, and Tdap (Tetanus-Diphtheria-Acellular Pertussis) vaccine. On the basis of age group, the market is categorized as adult and pediatric. On the basis of end-user, the market is categorized as hospitals, clinics, and vaccination centers.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the DTaP and Tdap vaccines market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The DTaP and Tdap vaccines market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting DTaP and Tdap vaccines market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely, North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the DTaP and Tdap vaccines market in these regions.
By Product Type
By Age Group
By End user
MARKET PLAYERS
The report covers key developments in the DTaP and Tdap vaccines market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from DTaP and Tdap Vaccines market are anticipated to have lucrative growth opportunities in the future with the rising demand for DTaP and Tdap vaccines in the global market. Below mentioned is the list of few companies engaged in the DTaP and Tdap vaccines market.
The report also includes the profiles of key players in DTaP and Tdap vaccines market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
Tdap (Tetanus, Diphtheria, Pertussis) and DTaP (Diphtheria, Tetanus, Pertussis) vaccines contain inactivated forms of the toxin generated by the bacteria that cause the three diseases. The term "inactivated forms" refers to a substance that no longer causes disease but does cause the body to develop antibodies that its immune to the toxins. DTaP is approved for children under the age of seven. Tdap, diphtheria, and pertussis vaccine with a reduced dose is approved for adolescents starting at age 11 and adults ages 19 to 64. It's known as a booster dose because it boosts immunity that has waned from vaccinations given between the ages of 4 and 6.
MARKET DYNAMIC
Factors driving the growth of the DTaP and Tdap vaccines market are the growing number of cases during late spring and early summer, coupled with rising adoption of pertussis vaccine. However, the high cost of vaccine development and inadequate access to vaccines in under-developed countries is expected to hamper the growth of the market. Moreover, increasing high birth rates and rising governments initiatives is anticipated to boost the market growth.
MARKET SCOPE
The "DTaP and Tdap Vaccines Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of DTaP and Tdap vaccines market with detailed market segmentation by product type, age group, and end user. The DTaP and Tdap vaccines market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in DTaP and Tdap vaccines market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The DTaP and Tdap vaccines market is segmented on the basis of product type, age group, and end user. Based on product type, the market is segmented as DTaP vaccine (Diphtheria-Tetanus-acellular Pertussis vaccine), TD (Tetanus and Diphtheria) vaccine, and Tdap (Tetanus-Diphtheria-Acellular Pertussis) vaccine. On the basis of age group, the market is categorized as adult and pediatric. On the basis of end-user, the market is categorized as hospitals, clinics, and vaccination centers.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the DTaP and Tdap vaccines market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The DTaP and Tdap vaccines market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting DTaP and Tdap vaccines market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely, North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the DTaP and Tdap vaccines market in these regions.
DTaP and Tdap Vaccines Market Report Analysis
DTaP and Tdap Vaccines Market
-
CAGR (2023 - 2031)XX% -
Market Size 2023
US$ XX Million -
Market Size 2031
US$ XX Million
Report Coverage
- Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Key future trends
- Detailed PEST/Porter’s Five Forces and SWOT analysis
- Industry landscape and competition analysis & recent developments
- Detailed company profiles
- Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
Key Players
- AJ Vaccines
- Bionet Asia
- GlaxoSmithKline plc GSK
- Johnson Johnson
- Massbiologics
- Meiji Holdings Co Ltd KM biologics co Ltd
- Merck Co Inc
- Panacea Biotec Ltd
- Sanofi
Regional Overview
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
By Product Type
- DTaP vaccine
- TD vaccine
- Tdap vaccine
By Age Group
- Adult
- Pediatric
By End user
- Hospitals
- Clinics
- Vaccination Centers
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
The report covers key developments in the DTaP and Tdap vaccines market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from DTaP and Tdap Vaccines market are anticipated to have lucrative growth opportunities in the future with the rising demand for DTaP and Tdap vaccines in the global market. Below mentioned is the list of few companies engaged in the DTaP and Tdap vaccines market.
The report also includes the profiles of key players in DTaP and Tdap vaccines market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- AJ Vaccines
- Bionet-Asia
- GlaxoSmithKline plc (GSK)
- Johnson & Johnson
- Massbiologics
- Meiji Holdings Co., Ltd. (KM biologics co., Ltd.)
- Merck & Co., Inc.
- Panacea Biotec Ltd.
- Sanofi
- Serum Institute of India Pvt. Ltd.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
DTaP and Tdap Vaccines Market Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ XX Million |
| Market Size by 2031 | US$ XX Million |
| Global CAGR (2023 - 2031) | XX% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Product Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
|
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
The List of Companies
1. AJ Vaccines
2. Bionet-Asia
3. GlaxoSmithKline plc (GSK)
4. Johnson & Johnson
5. Massbiologics
6. Meiji Holdings Co., Ltd. (KM biologics co., Ltd.)
7. Merck & Co., Inc.
8. Panacea Biotec Ltd.
9. Sanofi
10. Serum Institute of India Pvt. Ltd.
11. Protein Sciences Corporation
12. Novartis AG
13. Seqirus
14. Astellas Pharma US
15. Lanzhou Institute of Biological Products Co., Ltd
16. AstraZeneca
17. Emergent BioSolutions Inc.
1. AJ Vaccines
2. Bionet-Asia
3. GlaxoSmithKline plc (GSK)
4. Johnson & Johnson
5. Massbiologics
6. Meiji Holdings Co., Ltd. (KM biologics co., Ltd.)
7. Merck & Co., Inc.
8. Panacea Biotec Ltd.
9. Sanofi
10. Serum Institute of India Pvt. Ltd.
11. Protein Sciences Corporation
12. Novartis AG
13. Seqirus
14. Astellas Pharma US
15. Lanzhou Institute of Biological Products Co., Ltd
16. AstraZeneca
17. Emergent BioSolutions Inc.
Get Free Sample For